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Abstract
Background: Since 2003, the Global Fund has supported the scale-up of HIV/AIDS, tuberculosis and malaria control in 
low- and middle-income countries. This paper presents and discusses a methodology for estimating the lives saved 
through selected service deliveries reported to the Global Fund.
Methods: Global Fund-supported programs reported, by end-2007, 1.4 million HIV-infected persons on antiretroviral 
treatment (ARV), 3.3 million new smear-positive tuberculosis cases detected in DOTS (directly observed TB treatment, 
short course) programs, and 46 million insecticide-treated mosquito nets (ITNs) delivered. We estimated the 
corresponding lives saved using adaptations of existing epidemiological estimation models.
Results: By end-2007, an estimated 681,000 lives (95% uncertainty range 619,000-774,000) were saved and 1,097,000 
(993,000-1,249,000) life-years gained by ARV. DOTS treatment would have saved 1.63 million lives (1.09 - 2.17 million) 
when compared against no treatment, or 408,000 lives (265,000-551,000) when compared against non-DOTS 
treatment. ITN distributions in countries with stable endemic falciparum malaria were estimated to have achieved 
protection from malaria for 26 million of child-years at risk cumulatively, resulting in 130,000 (27,000-232,000) under-5 
deaths prevented.
Conclusions: These results illustrate the scale of mortality effects that supported programs may have achieved in 
recent years, despite margins of uncertainty and covering only selected intervention components. Evidence-based 
evaluation of disease impact of the programs supported by the Global Fund with international and in-country partners 
must be strengthened using population-level data on intervention coverage and demographic outcomes, information 
on quality of services, and trends in disease burdens recorded in national health information systems.
Background
Only in some five years, the Global Fund to Fight AIDS,
Tuberculosis and Malaria (Global Fund) has become a
major player in international health development. In
2005, the Global Fund provided 21% of international
funding for HIV/AIDS programs in low- and middle-
income countries, 67% for tuberculosis (TB), and 64% for
malaria[1]. By December 2007, it has approved a total of
US$ 10.1 billion proposals, in more than 550 grants in
136 countries, of which US$ 4.8 billion had been dis-
bursed to recipients in 134 countries[2]. As control effort
of the three diseases is scaled up, there is now consider-
able interest to show the scale of health benefits from
interventions supported.
For evaluation of disease impact, Global Fund recipi-
ents collect epidemiological data on relevant changes in
mortality and morbidity. Given the nature of the diseases
and interventions and data collection mechanisms, it may
take several years before impact becomes detectable. For
example, reductions in new HIV infections are inferred
retrospectively from prevalence trends over preceding
years. WHO and UNAIDS regularly publish regional-
level HIV incidence and prevalence estimates, using
country surveillance and survey data that often require
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two years to be released [3-7]. Similarly, all-cause under-
five mortality, a key impact indicator for malaria in areas
of high endemicity, is often measured in population-
based surveys with 3-5 year intervals[8]. Malaria-related
mortality reductions become apparent only 3-5 years
after they start, with the 'birth history' method[9]. The
consensus TB estimation model, applied to high-burden
countries by WHO with national TB programs[10,11],
relies on patient cohort data about treatment outcomes
from two preceding years.
In view of these data limitations, it is still early for the
impact of Global Fund support to be fully measured. As
an interim approach, we estimated the scale of lives
saved, by summarizing deaths averted from key service
delivery results reported by recipient programs. Interven-
tions considered are antiretroviral treatment (ARV),
Directly Observed TB Treatment, short-course (DOTS)
and insecticide-treated mosquito nets (ITN). Estimates of
their efficacies against mortality are available[7,12-17].
This paper presents and discusses the methodology for
this approach with estimates of lives saved through ser-
vice deliveries reported to the Global Fund between 2003
and end-2007.
Methods
Lives saved and, for ARV, life-years gained, were esti-
mated using mortality estimation models and assump-
tions used by UNAIDS, WHO Stop TB and Roll Back
Malaria. Models were adapted to use as main input ser-
vice delivery results available from recipient countries
(Table 1and below).
Service delivery results
Supported programs regularly report progress against
targets on standardized indicators[18]http://www.the-
globalfund.org, as the basis for performance-based fund-
ing[19]. Reported results are verified by independent
contractors. The Global Fund secretariat then aggregates
grant delivery results across the portfolio, for reporting
back to donors[20,21] (Table 2). For ARV, the validity and
extent of overlap are assessed with WHO and the US
President's Emergency Program for AIDS Relief (PEP-
FAR), resulting in harmonized numbers[22-24]. Results
from multi-country grants were excluded for simplicity.
AIDS mortality averted due to ARV
ARV programs routinely report to the Global Fund (and
other international organizations) on people currently on
ARV. This indicator forms a key input to the epidemio-
logical modelling package (known as Spectrum) that the
UNAIDS Reference Group on Estimates, Modelling, and
Projections[25] recommends for calculating lives saved
and life-years gained by ARV. Life-years gained is the pre-
ferred metric for population survival benefit[25], because
ARV extends life but does not cure infections.
Spectrum uses demographic data and estimates of
country HIV prevalence, incidence, mortality and ARV
coverage rates over time[25], to estimate epidemic trends
in the presence and (hypothetical) absence of ARV in
each country[24,26]. Spectrum assumes that all ARV is
provided to HIV-infected people in need of such treat-
ment, which is operationalized as a median of 3 years
before estimated time of AIDS-related deaths[26]. Sur-
vival at 12 months on ARV is assumed to be 85% for both
adults and children, after which each next year 5% of sur-
vivors would die[26]. People reported on treatment in
2004, 2005 or 2006 were assumed to have started in the
respective years and stayed on treatment through end-
2007, unless they had died. In a comparison scenario,
annual mortality was assumed to be 50% by 12 months,
and 100% by 24 months from starting to need ARV for
people not accessing the treatment[25]. 'Lives saved' by
2007 were calculated as the difference between cumula-
tive numbers of deaths with and without ARV.
These projections yielded average ratios of 'life-years
gained per patient-year of ARV', and 'lives saved per
patient on ARV', which varied among countries and over
calendar years according to varying stages of disease that
patients initiated ARV, indirect demographic effects
(restored fertility etc.), and dynamic effects of ARV,
through reduced viral load, on reducing HIV transmis-
sion. To subsequently obtain mortality effect estimates,
the regionally averaged ratios of 'life-years gained per
patient-year of ARV' over the period 2003-2007, and of
'lives saved per patient on ARV' at end-2007 were applied
to regionally summed ARV numbers reported by Global
Fund recipients at end-2007.
TB mortality averted due to DOTS
We estimated TB mortality based on numbers of new
smear-positive case detections in supported DOTS pro-
grams[18] and TB case fatality rates. For a few programs
reporting case detections without specifying the smear
status, we assumed that 50% of cases were smear-posi-
tive. All cases were assumed to start DOTS without delay.
Because of the long duration of TB treatment, we consid-
ered half of cases detected in each calendar year to con-
tribute to lives saved in that year, counting the other half
as savings during the next year (Table 1).
For DOTS, two comparison scenarios were considered.
The simplest comparison, consistent with the 'no inter-
vention' counterfactual scenario for ARV and ITNs, was
against no treatment. The alternative is against non-
DOTS treatment, which is commonly used in TB impact
evaluations[12,27], as DOTS programs provide better
treatment to patients who would otherwise have been
treated in sub-standard ways[28]. While not always clear-
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ing infection and stopping transmission, non-DOTS
treatment still often prevents the patient from dying[28].
Case fatality rates for DOTS, non-DOTS and no treat-
ment scenarios were available from WHO, stratified by
HIV and smear status. These country-specific rates were
combined with country-specific proportions of DOTS-
treated smear-positive TB cases that are HIV-positive, for
the year 2006[28].
Malaria-related mortality averted due to ITNs
In areas of sub-Saharan Africa with stable endemic falci-
parum malaria, effective use of ITNs results in averting
5.5 under-five deaths per 1000 children protected per
year[29] (Table 1). This efficacy was applied to estimate
mortality reductions resulting from ITN deliveries in
recipient programs in sub-Saharan Africa and in Papua
New Guinea, where falciparum malaria occurs of a simi-
lar endemicity[30]. Mortality among adults, from non-
falciparum malaria and in places with non-stable falci-
parum malaria was not estimated, due to limited evi-
dence of intervention effectiveness and lack of reliable
estimates of populations at risk[30].
Table 1: Assumptions used in estimations of lives saved from Global Fund-supported service deliveries.
Service Mortality reduction based on population coverage Population coverage estimated from 
service deliveries
Other assumptions
ARV Survival of people in need of ARV [25,26]: with ARV: 85% 
by 12 months, 95% over each next year without 
treatment: 50% by 12 months, 0% by 24 months.} 
Regional estimates of the average number of life-years 
gained per patient-year of (Global Fund-supported) 
ARV, derived by applying the Spectrum model [26] to 
UNAIDS estimates of national HIV prevalence, HIV 
mortality and ARV coverage (see Table 2) [24].
All people put on ARV are in need of ARV
Those on ARV as of December 2004 started 
treatment in 2004 (rather than earlier)Of 
people starting ARV in a given calendar year, 
starting dates are evenly distributed over 
that calendar year.
Region-specific 95% URs on 
mortality estimates from the 
Spectrum model [25,26]
DOTS Death rates for newly detected smear-positive cases 
(WHO Stop TB department, unpublished data):
DOTS:
HIV-positive: country-specific (cross-country average 
11%; 95% UR 6-21%)
HIV-negative: country-specific (cross-country average 
11%; 95% UR 6-20%)
Scenario (a) - No TB treatment:
HIV-positive: country-specific (cross-country average 
83%; 95% UR 70-99%)
HIV-negative: country-specific (cross-country average 
70%; 95% UR 55-75%)
Scenario (b) - non-DOTS treatment:
HIV-positive: country-specific (cross-country average 
31%; 95% UR 21-43%)
HIV-negative: country-specific (cross-country average 
24%; 95% UR 15-34%)
All smear-positive cases reported as detected 
are DOTS-treated
Half of lives saved occur in the year of 
reported case detection, and half in the next 
year.
For programs not reporting 
the smear status of new 
cases, 50% were assumed to 
be smear-positive
Proportions of smear-
positive TB cases that are 
HIV-positive are country-
specific estimates, with a 
cross-country average of 
12.3% (95% UR 10-15%) in 
2006 [28].
ITNs All-cause under-5 mortality falls by 5.5 (95% UR 3.4-7.7) 
per 1000 child-years of protection by ITNs, in areas of 
stable endemic falciparum malaria [29]
Each ITN distributed in a country with stable endemic falciparum malaria 
protects on average 0.73 child under-5 at risk [31].
Effective lifespan of an ITN is 1.5 years.
T Average of 1.1 child-year (0.55-2.2) of protection per ITN distributed, over 
an ITN's lifetime
ITNs reported in a given calendar year count as providing protection for half 
of that year and (a maximum of) 1.0 year thereafter.
Abbreviations: ARV = antiretroviral treatment; DOTS = directly observed treatment, short course; ITN = insecticide-treated mosquito net 
(including long-lasting insecticide nets). Numbers in brackets are 95% uncertainty ranges (UR).
Note: For ARV, in view of its life-extending but non-curative nature, 'lives saved' should be read to mean: the difference between cumulative 
deaths with and without ARV, i.e. the deaths averted or postponed due to ARV by Global Fund-supported programmes, over the reference period 
between 2003 and December 2007.
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We assumed that each ITN distributed resulted in an
average of 1.1 child-year of protection, over the lifetime
of the net. This assumption was based on:
• A median ratio of 0.73 between the proportion of
households possessing one or more ITNs and the pro-
portion of children under-5 that sleep under an ITN.
This was the ratio observed across 37 DHS and MICS
surveys conducted in malaria-endemic countries
between 2000 and 2006[31];
• An effective ITN lifespan of 1.5 years. This takes
into account that some Global Fund-supported
malaria programs also supported ITN re-impregna-
tions.
• 0.73 * 1.5 = 1.1.
The cumulative years of protection achieved per ITN
up to the date was calculated from the dates of ITN distri-
butions in each country: ITNs distributed before end-
2006 were counted as having been used for 1.5 years, and
ITNs distributed in 2007 counted for 0.5 years (see also
Table 2 and Additional file 1, Online Appendix).
Uncertainty ranges
95% uncertainty ranges (UR's) were calculated applying
the delta method[32] to the calculation of averted deaths,
keeping only first-order terms in the error expression and
combining 95% UR's of all input parameters (see Table 1).
For service delivery results, on-site verification had
revealed that in 2005-6 83% of country reports were
within a 20% margin, without systematic bias in either
direction (over-reporting or under-reporting)[20]. We
therefore assumed a 25% error on each country delivery
result, without dependency among countries.
For other parameters, errors were (conservatively)
assumed to be systematic rather than country-specific.
When summing lives saved across the 3 diseases, errors
in disease-specific estimates were taken as independent.
Results
HIV/AIDS
As of end-2007, 1.44 million people were reported to be
on ARV, in 91 supported HIV programs (Table 3). The
resulting number of life-years gained was 1,097,000 (95%
uncertainty range 993,000-1,249,000). With the 1.44 mil-
lion patients alive, 108,000 were estimated to have died by
end-2007, whereas, had ARV not been provided, 782,000
would have died. An estimated 681,000 deaths (619,000-
774,000) were averted, or 681,000 lives saved, due to ARV
scale-up by end-2007 (Figure 1).
Tuberculosis
Supported TB programs in 68 countries reported a
cumulative 3.3 million smear-positive TB case detections
by end-2007 (Table 4). Out of these, 272,000 were esti-
mated to have died in spite of DOTS. Using 'without-
treatment' as comparison scenario, deaths would have
amounted to 1.9 million, resulting in an estimated 1.63
million lives saved (1.09 - 2.17 million). Under non-
DOTS treatment, by contrast, 680,000 smear-positive
cases would have died, corresponding to an estimated
408,000 lives saved (265,000-551,000) (Figure 1).
Malaria
By December 2007, 46 million ITNs had been distributed
across 62 countries. Over 38 million ITNs were distrib-
uted in 35 African countries with stable endemic falci-
parum malaria; 231,000 in Papua New Guinea, and 7.4
million in lower-endemic areas (Table 5).
Across sub-Saharan Africa and Papua New Guinea, the
average duration of past usage of ITNs distributed was
0.89 years by end-2007, resulting in a cumulative total of
nearly 26 million of child-years of protection by end-2007
(Table 5).
These 36 countries had around 3.8 million under-5
deaths in 2006. Against this baseline, we estimated that
Global Fund-supported ITNs had averted 130,000 deaths
(27,000-232,000) up to end-2007 (Figure 1).
Total lives saved
Adding the estimated lives saved from ARV, DOTS and
ITN, without adjustment for interactions between dis-
eases or the possibility of persons benefiting from multi-
ple interventions, total lives saved by Global Fund-
supported programs would stand at around 2.44 million
Table 2: Results of three key service deliveries for Global Fund-supported programs
Dec-04 Dec-05 Dec-06 Dec-07
Current ARVs 130,000 384,000 770,000 1,450,000
Cumulative DOTS 385,000 1,000,000 2,000,000 3,310,000
Cumulative ITNs 1,350,000 7,700,000 18,000,000 45,600,000

























































Table 3: Estimation of lives saved by Global Fund-supported ARV cumulatively between 2003 and December 2007.
Region Countries withGF-
supportedARV programme
People currently on ARV, 
end-2007
Cumulative life-years on 
ARV,2003-2007
Average lives saved per person 
currently on ARV, end-2007*
East Africa 11 460,228 807,514 0.466
Western Africa 17 127,344 257,022 0.466
Southern Africa 9 496,449 864,069 0.466
North Africa & Middle East 10 21,383 28,104 0.466
South Asia 4 102,545 123,989 0.502
East Asia and The Pacific 8 157,602 349,257 0.502
Eastern Europe & Central Asia 16 17,667 28,165 0.352
Latin America & Caribbean 16 64,401 138,682 0.447
Global total 91 1,447,619 2,596,804 0.466
95% Uncertainty range (1,410,000-1,486,000)
Region Lives saved by end-2007 Average life-years gained per 
patient-year of ARV, 2003-7*
Life-years gained up to end-2007
(95% UR) (95% UR)
East Africa 214,538 (201,129-241,355) 0.424 342,386 (308,860-392,364)
Western Africa 59,362 (55,652-66,782) 0.424 108,977 (99,488-124,118)
Southern Africa 231,423 (216,959-260,351) 0.424 366,365 (328,202-421,405)
North Africa & Middle East 9,968 (9,345-11,214) 0.424 11,916 (10,715-13,679)
South Asia 51,505 (37,599-67,987) 0.443 54,927 (38,585-73,797)
East Asia and The Pacific 79,159 (57,786-104,489) 0.443 154,721 (110,765-206,085)
Eastern Europe & Central Asia 6,224 (4,419-9,634) 0.314 8,844 (6,220-13,722)
Latin America & Caribbean 28,813 (21,898-44,314) 0.351 48,677 (36,605-75,042)
























































ARV service delivery results are from country reports to Global Fund secretariat. The table excludes multi-country grants in the Americas and Western Pacific. Country groupings, including 
certain regions, are as per the Global Fund regional categorizations www.theglobalfund.org. HIV survival assumptions from the UNAIDS 2007 consensus epidemiological model package 
[24]. Proportional errors are shown for the two sources of error considered: mortality assumptions used in the Spectrum demographic model [26].
* weighted by country population size.
UR = 95% Uncertainty range.
Table 3: Estimation of lives saved by Global Fund-supported ARV cumulatively between 2003 and December 2007. (Continued)
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(1.74-3.18 million) by December 2007. Alternatively,
when using non-DOTS treatment as comparison (instead
of no treatment), lives saved sum to 1.22 million
(911,000-1,557,000).
Discussion
The presented estimates of lives saved and life-years
gained by Global Fund-supported ARV, DOTS and ITNs
indicate the magnitude of mortality reductions achieved
by recipient programs. While not being an actual mea-
surement or formal evaluation of program impact, the
estimations allow the Global Fund to gauge progress as
service delivery reports from programs accumulate.
The estimates do not reflect the whole spectrum of
interventions supported. Notably, HIV infections averted
by prevention services will in future save lives from AIDS,
but cannot readily be estimated from routine delivery
reports. Effective HIV prevention often results from a
multi-sectoral package of services[33-36], and infections
prevented for a given level of intervention coverage vary
among countries depending on local HIV incidence rates
and transmission modes. Methods to estimate HIV infec-
tions averted need urgent development[37].
For malaria, artemisinin-based combination treatments
(ACTs) probably have important mortality effects. By
December 2007, Global Fund-supported programs had
delivered over 24 million ACT courses, across 49 coun-
tries. The effectiveness of ACTs against mortality has not
been established through randomized trials and will
depend on the timeliness of and compliance with treat-
ment; proportions of ACTs for true malaria episodes
(rather than misused for non-malarial fevers); possible
effects of ACTs on preventing repeat episodes due to
recrudescent infection; and the comparison scenario (no
treatment or ineffective mono-therapy). The presented
model furthermore excluded indoor residual spraying
(IRS). As more knowledge becomes available, ACT and
IRS should be included in lives saved estimation.
The gap-filling nature of Global Fund financing makes
it difficult to define a specific contribution as distinct
from other donors and (pre-)existing in-country efforts.
Some programs, particularly HIV and TB, report pro-
gram-wide results covering all contributions from multi-
ple domestic and international funding sources to the
Global Fund, which promotes program supports rather
than a project approach. Lives saved result from collec-
tive efforts of in-country programs, to which the Global
Fund contributes alongside other partners. For malaria,
on the other hand, total service deliveries covering all
partners' contributions considerably outnumber results
reported to the Global Fund: e.g. in 2006 alone, 63 million
ITNs were produced worldwide[31]. For ARV, the
1,439,000 life-years saved represents around 33% of a
total 3.2 million estimated life-years saved in low- and
middle-income countries by end-2007[24]. The 33%
share is somewhat less than approximately 50% share in
ARV results (a total of 2.9 million as of end-2007[24]),
because some large ARV programs with support from
Global Fund (e.g., Brazil) had provided people on ARV
much longer, with larger effects.
Several limitations and caveats concerning input data
and assumptions must be acknowledged. Errors may
occur at any stages. Misclassification of smear positivity
for TB is one example. While service delivery numbers
may be imprecise and performance-based funding may
provide incentives for over-reporting, the errors are not
systematically in one direction, so that aggregated portfo-
lio results should roughly reflect what was delivered[20].
In reality, results at mid- and end-year released by the
Global Fund secretariat are significantly conservative
because results always have reporting delays but only
actual results available at the time of data compilation are
aggregated without projecting to release dates. Aggrega-
tion at country level is done also in a conservative man-
ner to avoid double counting. Data quality issues
nevertheless highlight an urgent need to strengthen
national monitoring and health information systems.
The presented methodology was designed exclusively
to produce a portfolio-aggregate indication of global-level
health gain, although we used certain country-specific
input assumptions and presented estimates by regional
break-down. Country-specific evaluations would, in con-
trast, require more refined methods and inputs.
Figure 1 Estimated lives saved by Global Fund-supported ARV, 
DOTS and ITNs, cumulatively between 2003 and end-2007. Notes: 
• For DOTS, two alternative estimations are shown that differ in the 
counterfactual scenarios (see description in Methods). • Not included 
in the lives saved estimations are the - relatively small - numbers of ser-
vice deliveries through multi-country grants (see Tables 3, 4 and 5). • Er-
ror bars represent 95% uncertainty ranges on the estimates, as 
described in Methods. ARV = antiretroviral treatment; DOTS = directly 

















































































Table 4: Estimation of lives saved by DOTS case detections and treatments in Global Fund-supported programs, cumulatively between 2003 and December 2007.
Region Countries with GF-supported
DOTS programme




Cumulative lives saved (95% UR)
Counterfactual scenario: Counterfactual scenario:
No treatment Non-DOTS treatment
East Africa 7 448,243 363,794 223,574 (128,704-318,445) 76,019 (42,182-109,856)
Western Africa 10 109,806 87,668 53,692 (31,794-75,591) 18,205 (10,396-26,015)
Southern Africa 6 239,144 208,153 133,546 (75,230-191,862) 46,957 (25,593-68,320)
North Africa & Middle East 9 68,195 45,438 26,634 (15,708-37,560) 6,342 (2,912-9,772)
Eastern Europe & Central Asia 10 72,345 53,023 26,125 (15,558-36,691) 1,530 (370-2,690)
South Asia 7 554,726 382,333 230,612 (133,671-327,553) 75,654 (41,271-110,037)
East Asia and the Pacific 9 1,774,876 1,524,979 916,232 (541,056-1,291,408) 180,256 (94,065-266,448)
Latin America & Caribbean 10 44,926 35,418 21,205 (12,588-29,823) 3,182 (1,620-4,743)
Total 68 3,312,261 2,700,805 1,632,000 408,000
95% Uncertainty range (3,211,843 -3,412,679) (2,618,925 -2,782,685) (1,094,000-2,169,000) (265,000-551,000)
DOTS results are from country reports to Global Fund secretariat. Table excludes a multi-country grant in the Western Pacific. Country groupings, including certain regions, are as per the Global 
Fund regional categorizations www.theglobalfund.org. Country-specific assumptions on proportions of smear-positive TB cases that are HIV-infected, and case fatality rates with and without DOTS 
were provided by the WHO Stop TB department (unpublished data).
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Table 5: Estimation of child-years of protection achieved with Global Fund-supported ITN deliveries and associated lives 
saved from malaria cumulatively between 2003 and December 2007.




East Africa 22,520,505 13,603,974 66,806 (11,134-122,477)
Burundi 1,055,968 787,845
Comoros 93,000 46,163









Western Africa 7,084,987 6,217,647 28,896 (5,293-52,499)
Benin 359,371 400,141









Sao Tome & Principe 53,974 9,771
Senegal 445,470 351,348
Sierra Leone 124,669 107,617
Togo 420,000 461,141














Yemen 295,075 Not included in Lives saved estimation
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The largest uncertainties in these estimates lie in the
epidemiological models and their basic (cross-country)
assumptions. The 2007 UNAIDS model for estimating
HIV-related deaths[25] may be possibly optimistic in
assuming 5-15% annual mortality on ARV, since cohort
studies in resource-poor settings found up to 27% mortal-
ity within the first year, and substantial losses to follow-
up which may include some additional mortality[38,39].
Given that ARV reporting to Global Fund does not
include an explicit dimension of treatment quality or
patient retention, some proportion of treatments deliv-
ered are likely to be of less good quality and clinical out-
come than is typical in western settings or in research
cohorts in resource-poor settings.
For TB, lives saved depend critically on the comparison
scenario (Figure 1). While a simplistic comparison
against 'no-treatment' is most consistent across the ser-
vices studied, this scenario may be less appropriate for
DOTS (compared to ARV and ITNs), given the relatively
high effectiveness and potential availability of non-DOTS
treatment[12,27,28]. The purpose of the paper is to indi-
cate the overall scale of programs rather than additional
impact due to scale-ups.
Our estimate of lives saved by Global Fund-supported
ITNs depends critically on assumptions to convert ITN
deliveries into child-years of protection. The assumption
that each ITN distributed provides an average 1.1 child-
year of protection (see Methods) is simplistic and proba-
bly conservative, because: (i) some 38% of ITNs distribu-
tions reported by supported programs were long-lasting
insecticidal nets (LLINs) that remain effective through-
out their lifetime of typically 3-4 years[40]; (ii) even for
conventional ITNs, the assumed 1.5-year lifespan may be
short in view of insecticide re-impregnations supported
through Global Fund grants[41], and (iii) ITN usage was
estimated based on 2000-06 surveys, but increased funds
also support behavior change communication activities.
Estimates of child protection by ITNs should be validated
and improved based on country-specific coverage data,
forthcoming from household surveys in many recipient
countries. Since recent surveys demonstrated significant
increases in ITN usage among under-fives[31,42], lives
saved from malaria are expected to increase rapidly over
the coming years.
There is reasonable consensus about the efficacy of
ITNs against mortality in children exposed to endemic
falciparum malaria, for given levels of coverage, in all
recent malaria impact models[14], including a consensus
model under development by UNICEF and WHO[43].
Malaria effect estimates were, nonetheless, conservative
because we did not consider mortality averted outside
sub-Saharan Africa and Papua New Guinea. In any case,
considerable uncertainties about the size and geographi-
cal distribution of populations exposed to stable endemic
malaria[30] contribute to relatively wide uncertainty
ranges, compared to ARV and DOTS (error bars in Figure
1).
The presented uncertainty ranges, particularly for ARV
and DOTS, may be minimum intervals, which do not
capture the complex chain of factors that intervene
between service delivery counts, population coverage and
impact, such as quality of services including (mis-)diag-
nosis, drug quality, patient counselling and support to
promote patient retention and treatment adherence. Peri-
odic evaluation of quality of services must therefore be
added to program progress tracking and performance
evaluation.
East Asia (#) 4,505,913 1,391 (117-2,665)
Papua New Guinea 231,000 260,955
South Asia 2,178,314 Not included in Lives saved estimation
Eastern Europe & Central Asia 48,400 Not included in Lives saved estimation
Latin America & Caribbean 602,895 Not included in Lives saved estimation
TOTAL 45,233,035
TOTAL: sub-Saharan Africa + PNG 38,240,506 25,910,265 130,000 (27,000-232,000)
ITN results are from country reports to Global Fund secretariat. Table excludes multi-country grants in the Western Pacific and Andean Americas. 
Country groupings, including certain regions, are as per the Global Fund regional categorizations www.theglobalfund.org. PNG = Papua New 
Guinea.
$$In the North Africa & Middle East region, Yemen was included in the regional totals for ITN numbers and for population at risk, but not in the 
estimation of Lives saved. Yemen was not included in the total for 'sub-Saharan Africa + PNG'.
# All 9 East Asia countries were included in ITN numbers, but only Papua New Guinea was included in the estimation of Lives saved.
* Weighted by country population size.
Example calculations of child-years of protection achieved and lives saved by country-reported ITN distributions are given in Additional file 1.
Table 5: Estimation of child-years of protection achieved with Global Fund-supported ITN deliveries and associated lives 
saved from malaria cumulatively between 2003 and December 2007. (Continued)
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Longer-term, improved approaches to measuring dis-
ease impact are essential in low- and middle-income
countries. To enable this and to evaluate its institutional
performance and partners context, the Global Fund rec-
ommends that programs spend 5-10% of grant budgets
on strengthening monitoring and evaluation systems as
well as supporting vital registration. Furthermore, the
Global Fund Board has commissioned an independent
Five-Year Evaluation including impact evaluations rein-
forcing quality data collection and analysis in 20 coun-
tries[20,44].
Conclusion
The presented estimates indicate the scale of mortality
effects that Global Fund-supported programs may have
achieved over recent years. While the numbers carry
great margins of uncertainty and cover only selected pro-
gram components, they reflect the best information
available to date. Evidence-based evaluation of the impact
of HIV/AIDS, TB and malaria programs supported by the
Global Fund and other partners is ongoing and must be
further strengthened to maximize health gain. Great
improvements will be made by triangulating service
delivery reports with population-level data on interven-
tion coverage and demographic outcomes, information
on quality of services, and trends in health facility disease
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